Sifalimumab

立即咨询

Sifalimumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1006877-41-3

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议
10mg	电议
50mg	电议
100mg	电议

产品名称

MEDI-545
MDX 1103

产品介绍

Sifalimumab (MEDI-545) 是一种anti-IFNα单克隆抗体，通过与多种干扰素-α 亚型结合来抑制异常的免疫活动。Sifalimumab 可用于系统性红斑狼疮 (SLE) 的研究。

生物活性

Sifalimumab (MEDI-545) is ananti-IFNαmonoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research^[1]^[2].

体外研究
(In Vitro)

Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG^[2].

Cell Viability Assay^[2]

Cell Line:	U-87MG cells and AGS lymphocytes
Concentration:	3-36 μg/well
Incubation Time:	72 hours
Result:	Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05).

体内研究
(In Vivo)

Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration^[2].

Animal Model:	Wild-type male BALB/c mice^[2]
Dosage:	30 mg/kg and 3 μg/g
Administration:	Subcutaneous injection; 30 mg/kg and 3 μg/g
Result:	Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P< 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05).

Clinical Trial

性状

Liquid

CAS 号

1006877-41-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.